๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

[Methods and Principles in Medicinal Chemistry] Hit and Lead Profiling Volume 43 || In Vitro Safety Pharmacology Profiling: An Important Tool to Decrease Attrition

โœ Scribed by Faller, Bernard; Urban, Laszlo


Book ID
120029708
Publisher
Wiley
Year
2009
Tongue
German
Weight
310 KB
Edition
1
Category
Article
ISBN
3527323317

No coin nor oath required. For personal study only.

โœฆ Synopsis


The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in conjunction with the analysis of physicochemical properties of the potential drug molecules, enabling an informed selection of drug development candidates before they enter clinical trials.

By addressing both drug efficiency and drug safety, this modern practical reference shows how each individual aspect figures in shaping the key decisions on which the entire drug development process hinges. The result is a complete toolbox for assessing the risk/benefit ratio for any novel compound, using both in vitro and in silico methods.

Following a brief introduction to the necessities of filtering and risk assessment, the two equally important aspects of pharmacological (ADME) and safety (toxicity) profiling are covered in separate parts. The whole of the fourth and final part is devoted to organ-specific toxicity assays for the liver, heart, kidney and blood, as well as profiling for autoimmune reactions.

Invaluable know-how for every medicinal chemist and drug developer.


๐Ÿ“œ SIMILAR VOLUMES


[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 231 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 397 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 224 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 532 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 199 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che
โœ Faller, Bernard; Urban, Laszlo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley ๐ŸŒ German โš– 242 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con